Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma.

Moodley S, Lian EY, Crupi MJF, Hyndman BD, Mulligan LM.

Lung Cancer. 2020 Apr;142:123-131. doi: 10.1016/j.lungcan.2020.02.004. Epub 2020 Feb 22.

PMID:
32146264
2.

GGA3-mediated recycling of the RET receptor tyrosine kinase contributes to cell migration and invasion.

Crupi MJF, Maritan SM, Reyes-Alvarez E, Lian EY, Hyndman BD, Rekab AN, Moodley S, Antonescu CN, Mulligan LM.

Oncogene. 2020 Feb;39(6):1361-1377. doi: 10.1038/s41388-019-1068-z. Epub 2019 Oct 23.

PMID:
31645646
3.

A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis.

Azad T, Nouri K, Janse van Rensburg HJ, Maritan SM, Wu L, Hao Y, Montminy T, Yu J, Khanal P, Mulligan LM, Yang X.

Oncogene. 2020 Jan;39(2):334-355. doi: 10.1038/s41388-019-0988-y. Epub 2019 Sep 2.

PMID:
31477837
4.

GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential.

Mulligan LM.

Front Physiol. 2019 Jan 7;9:1873. doi: 10.3389/fphys.2018.01873. eCollection 2018. Review.

5.

65 YEARS OF THE DOUBLE HELIX: Exploiting insights on the RET receptor for personalized cancer medicine.

Mulligan LM.

Endocr Relat Cancer. 2018 Aug;25(8):T189-T200. doi: 10.1530/ERC-18-0141. Epub 2018 May 9. Review.

PMID:
29743166
6.

The evolving clinical, genetic and therapeutic landscape of multiple endocrine neoplasia type 2.

Moodley S, Weber F, Mulligan LM.

Endocr Relat Cancer. 2018 Feb;25(2):E1-E4. doi: 10.1530/ERC-17-0488. No abstract available.

PMID:
29348305
7.

Happy 20th anniversary MEN1: from positional cloning to gene function restoration.

Weber F, Mulligan LM.

Endocr Relat Cancer. 2017 Oct;24(10):E7-E11. doi: 10.1530/ERC-17-0346. No abstract available.

PMID:
28899948
8.

Differential recruitment of E3 ubiquitin ligase complexes regulates RET isoform internalization.

Hyndman BD, Crupi MJF, Peng S, Bone LN, Rekab AN, Lian EY, Wagner SM, Antonescu CN, Mulligan LM.

J Cell Sci. 2017 Oct 1;130(19):3282-3296. doi: 10.1242/jcs.203885. Epub 2017 Aug 9.

9.

An Efficient and Flexible Cell Aggregation Method for 3D Spheroid Production.

Maritan SM, Lian EY, Mulligan LM.

J Vis Exp. 2017 Mar 27;(121). doi: 10.3791/55544.

10.

Differential roles of RET isoforms in medullary and papillary thyroid carcinomas.

Lian EY, Maritan SM, Cockburn JG, Kasaian K, Crupi MJ, Hurlbut D, Jones SJ, Wiseman SM, Mulligan LM.

Endocr Relat Cancer. 2017 Jan;24(1):53-69. Epub 2016 Nov 21.

PMID:
27872141
11.

Progress and potential impact of RET kinase targeting in cancer.

Mulligan LM.

Expert Rev Proteomics. 2016 Jul;13(7):631-3. doi: 10.1080/14789450.2016.1205491. Epub 2016 Jul 4. No abstract available.

PMID:
27337654
12.

Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma.

Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, Davey S.

Curr Oncol. 2016 Jun;23(3):e171-8. doi: 10.3747/co.23.3028. Epub 2016 Jun 9.

13.

Distinct Temporal Regulation of RET Isoform Internalization: Roles of Clathrin and AP2.

Crupi MJ, Yoganathan P, Bone LN, Lian E, Fetz A, Antonescu CN, Mulligan LM.

Traffic. 2015 Nov;16(11):1155-73. doi: 10.1111/tra.12315. Epub 2015 Sep 21.

14.

ATM gene mutations in sporadic breast cancer patients from Brazil.

Mangone FR, Miracca EC, Feilotter HE, Mulligan LM, Nagai MA.

Springerplus. 2015 Jan 15;4:23. doi: 10.1186/s40064-015-0787-z. eCollection 2015.

15.

Cell surface biotinylation of receptor tyrosine kinases to investigate intracellular trafficking.

Crupi MJ, Richardson DS, Mulligan LM.

Methods Mol Biol. 2015;1233:91-102. doi: 10.1007/978-1-4939-1789-1_9.

PMID:
25319892
16.

RET revisited: expanding the oncogenic portfolio.

Mulligan LM.

Nat Rev Cancer. 2014 Mar;14(3):173-86. doi: 10.1038/nrc3680. Review.

PMID:
24561444
17.

Alternative splicing results in RET isoforms with distinct trafficking properties.

Richardson DS, Rodrigues DM, Hyndman BD, Crupi MJ, Nicolescu AC, Mulligan LM.

Mol Biol Cell. 2012 Oct;23(19):3838-50. doi: 10.1091/mbc.E12-02-0114. Epub 2012 Aug 8.

18.

Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease.

Hyndman BD, Gujral TS, Krieger JR, Cockburn JG, Mulligan LM.

Hum Mutat. 2013 Jan;34(1):132-42. doi: 10.1002/humu.22170. Epub 2012 Aug 23.

PMID:
22837065
19.

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2.

Wagner SM, Zhu S, Nicolescu AC, Mulligan LM.

Clinics (Sao Paulo). 2012;67 Suppl 1:77-84. Review.

20.

Novel mutations at RET ligand genes preventing receptor activation are associated to Hirschsprung's disease.

Ruiz-Ferrer M, Torroglosa A, Luzón-Toro B, Fernández RM, Antiñolo G, Mulligan LM, Borrego S.

J Mol Med (Berl). 2011 May;89(5):471-80. doi: 10.1007/s00109-010-0714-2. Epub 2011 Jan 5.

PMID:
21206993
21.

RET-mediated cell adhesion and migration require multiple integrin subunits.

Cockburn JG, Richardson DS, Gujral TS, Mulligan LM.

J Clin Endocrinol Metab. 2010 Nov;95(11):E342-6. doi: 10.1210/jc.2010-0771. Epub 2010 Aug 11.

PMID:
20702524
22.

The highs and lows of PITX2: comment on: Huang, et al. Cell Cycle 2010; 9:1333-41.

Mulligan LM.

Cell Cycle. 2010 May 15;9(10):1874. Epub 2010 May 15. No abstract available.

PMID:
20505325
23.

High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene.

Toledo RA, Wagner SM, Coutinho FL, Lourenço DM Jr, Azevedo JA, Longuini VC, Reis MT, Siqueira SA, Lucon AM, Tavares MR, Fragoso MC, Pereira AA, Dahia PL, Mulligan LM, Toledo SP.

J Clin Endocrinol Metab. 2010 Mar;95(3):1318-27. doi: 10.1210/jc.2009-1355. Epub 2010 Jan 15.

PMID:
20080836
24.

Direct visualization of vesicle maturation and plasma membrane protein trafficking.

Richardson DS, Mulligan LM.

J Fluoresc. 2010 Jan;20(1):401-5. doi: 10.1007/s10895-009-0548-x. Epub 2009 Oct 13.

PMID:
19823924
25.

Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.

Richardson DS, Gujral TS, Peng S, Asa SL, Mulligan LM.

Cancer Res. 2009 Jun 1;69(11):4861-9. doi: 10.1158/0008-5472.CAN-08-4425.

26.

RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation.

Hickey JG, Myers SM, Tian X, Zhu SJ, V Shaw JL, Andrew SD, Richardson DS, Brettschneider J, Mulligan LM.

Genes Chromosomes Cancer. 2009 May;48(5):429-40. doi: 10.1002/gcc.20653.

PMID:
19226610
27.

A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma.

Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JW, Mulligan LM.

Cancer Res. 2008 Mar 1;68(5):1338-46. doi: 10.1158/0008-5472.CAN-07-6052.

28.

RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Lai AZ, Gujral TS, Mulligan LM.

Endocr Pathol. 2007 Summer;18(2):57-67. Review.

PMID:
17916994
29.

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.

Gujral TS, Singh VK, Jia Z, Mulligan LM.

Cancer Res. 2006 Nov 15;66(22):10741-9.

30.

Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.

Gujral TS, Mulligan LM.

Ann N Y Acad Sci. 2006 Aug;1073:234-40.

PMID:
17102091
31.

RET ligand-induced internalization and its consequences for downstream signaling.

Richardson DS, Lai AZ, Mulligan LM.

Oncogene. 2006 May 25;25(22):3206-11.

PMID:
16418724
32.

From genes to decisions: evolving views of genotype-based management in MEN 2.

Mulligan LM.

Cancer Treat Res. 2004;122:417-28. Review.

PMID:
16209059
33.

A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2.

Vanhorne JB, Andrew SD, Harrison KJ, Taylor SA, Thomas B, McDonald TJ, Ainsworth PJ, Mulligan LM.

Oncogene. 2005 Feb 3;24(6):1091-7.

PMID:
15592530
34.

The RET receptor is linked to stress response pathways.

Myers SM, Mulligan LM.

Cancer Res. 2004 Jul 1;64(13):4453-63.

35.

Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway.

Andrew SD, Capes-Davis A, Delhanty PJ, Marsh DJ, Mulligan LM, Robinson BG.

Gene. 2002 Sep 18;298(1):9-19.

PMID:
12406571
37.

Conservation of RET proto-oncogene splicing variants and implications for RET isoform function.

Carter MT, Yome JL, Marcil MN, Martin CA, Vanhorne JB, Mulligan LM.

Cytogenet Cell Genet. 2001;95(3-4):169-76.

PMID:
12063395
38.

Multiple endocrine neoplasia type 2: molecular aspects.

Mulligan LM.

Front Horm Res. 2001;28:81-102. Review. No abstract available.

PMID:
11443855
39.

Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease.

Vanhorne JB, Gimm O, Myers SM, Kaushik A, von Deimling A, Eng C, Mulligan LM.

Hum Genet. 2001 May;108(5):409-15.

PMID:
11409869
40.
41.

Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.

Gläsker S, Bender BU, Apel TW, van Velthoven V, Mulligan LM, Zentner J, Neumann HP.

J Neurol Neurosurg Psychiatry. 2001 May;70(5):644-8.

42.

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Hansford JR, Mulligan LM.

J Med Genet. 2000 Nov;37(11):817-27. Review.

43.

Sp1 and Sp3 transactivate the RET proto-oncogene promoter.

Andrew SD, Delhanty PJ, Mulligan LM, Robinson BG.

Gene. 2000 Oct 3;256(1-2):283-91.

PMID:
11054558
44.

Characterisation of the human GFRalpha-3 locus and investigation of the gene in Hirschsprung disease.

Onochie CI, Korngut LM, Vanhorne JB, Myers SM, Michaud D, Mulligan LM.

J Med Genet. 2000 Sep;37(9):674-9.

45.

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.

Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C.

Am J Pathol. 1999 Oct;155(4):1253-60.

46.

Mutation and deletion analysis of GFR alpha-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours.

Gimm O, Gössling A, Marsh DJ, Dahia PL, Mulligan LM, von Deimling A, Eng C.

Br J Cancer. 1999 May;80(3-4):383-6.

47.

Investigation of germline GFR alpha-1 mutations in Hirschsprung disease.

Myers SM, Salomon R, Goessling A, Pelet A, Eng C, von Deimling A, Lyonnet S, Mulligan LM.

J Med Genet. 1999 Mar;36(3):217-20.

48.

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboué B, Latham WC, Eng C, Mulligan LM, Longy M.

Br J Cancer. 1999 Feb;79(5-6):718-23.

49.

Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma.

Eng C, Thomas GA, Neuberg DS, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Williams ED, Ponder BA.

J Clin Endocrinol Metab. 1998 Dec;83(12):4310-3.

PMID:
9851769
50.

Analysis of PTEN and the 10q23 region in primary prostate carcinomas.

Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM.

Oncogene. 1998 Apr 2;16(13):1743-8.

Supplemental Content

Loading ...
Support Center